Freedberg K, Kumarasamy N, Borre E, Ross E, Mayer K, Losina E
AIDS Res Hum Retroviruses. 2018; 34(6):486-497.
PMID: 29620932
PMC: 5994680.
DOI: 10.1089/AID.2017.0258.
Ndawinz J, Anglaret X, Delaporte E, Koulla-Shiro S, Gabillard D, Minga A
Bull World Health Organ. 2015; 93(8):521-8.
PMID: 26478609
PMC: 4581657.
DOI: 10.2471/BLT.14.147892.
Kimmel A, Resch S, Anglaret X, Daniels N, Goldie S, Danel C
Cost Eff Resour Alloc. 2012; 10(1):12.
PMID: 22992315
PMC: 3502124.
DOI: 10.1186/1478-7547-10-12.
Anglaret X, Scott C, Walensky R, Ouattara E, Losina E, Moh R
Antivir Ther. 2012; 18(1):45-55.
PMID: 22809695
PMC: 3893045.
DOI: 10.3851/IMP2231.
Pho M, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler L
PLoS One. 2012; 7(4):e36001.
PMID: 22558301
PMC: 3340407.
DOI: 10.1371/journal.pone.0036001.
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.
Pantazis N, Morrison C, Amornkul P, Lewden C, Salata R, Minga A
PLoS One. 2012; 7(3):e32369.
PMID: 22412867
PMC: 3295758.
DOI: 10.1371/journal.pone.0032369.
Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.
Ouattara E, Anglaret X, Wong A, Chu J, Hsu H, Danel C
AIDS. 2012; 26(5):625-34.
PMID: 22398569
PMC: 3834615.
DOI: 10.1097/QAD.0b013e328350fbfb.
AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire.
Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B
Clin Infect Dis. 2011; 54(5):714-23.
PMID: 22173233
PMC: 3275759.
DOI: 10.1093/cid/cir898.
CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa.
Lewden C, Gabillard D, Minga A, Ekouevi D, Avit D, Konate I
J Acquir Immune Defic Syndr. 2011; 59(2):213-9.
PMID: 22027874
PMC: 3921663.
DOI: 10.1097/QAI.0b013e31823b837e.
CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.
Minga A, Lewden C, Gabillard D, Bomisso G, Toni T, Emieme A
AIDS. 2011; 25(6):819-23.
PMID: 21412060
PMC: 3921664.
DOI: 10.1097/QAD.0b013e32834625d3.
Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.
Messou E, Chaix M, Gabillard D, Minga A, Losina E, Yapo V
J Acquir Immune Defic Syndr. 2010; 56(4):356-64.
PMID: 21191309
PMC: 3050083.
DOI: 10.1097/QAI.0b013e3182084b5a.
Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire.
Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, Deuffic-Burban S
PLoS One. 2010; 5(10):e13414.
PMID: 20976211
PMC: 2955519.
DOI: 10.1371/journal.pone.0013414.
Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Côte d'Ivoire.
Minga A, Lewden C, Dohoun L, Abo Y, Emieme A, Coulibaly A
AIDS Res Hum Retroviruses. 2010; 26(9):991-5.
PMID: 20707728
PMC: 3531999.
DOI: 10.1089/aid.2009.0309.
CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.
Yazdanpanah Y, Wolf L, Anglaret X, Gabillard D, Walensky R, Moh R
Antivir Ther. 2010; 15(3):351-61.
PMID: 20516555
PMC: 3220615.
DOI: 10.3851/IMP1542.
Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.
Kimmel A, Weinstein M, Anglaret X, Goldie S, Losina E, Yazdanpanah Y
J Acquir Immune Defic Syndr. 2010; 54(3):258-68.
PMID: 20404739
PMC: 3174771.
DOI: 10.1097/QAI.0b013e3181d0db97.
Low HIV testing rates among tuberculosis patients in Kampala, Uganda.
Sendagire I, Schreuder I, Mubiru M, Schim van der Loeff M, Cobelens F, Konde-Lule J
BMC Public Health. 2010; 10(1):177.
PMID: 20356353
PMC: 2859398.
DOI: 10.1186/1471-2458-10-177.
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.
Losina E, Toure H, Uhler L, Anglaret X, Paltiel A, Balestre E
PLoS Med. 2009; 6(10):e1000173.
PMID: 19859538
PMC: 2762030.
DOI: 10.1371/journal.pmed.1000173.
Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.
Korenromp E, Williams B, Schmid G, Dye C
PLoS One. 2009; 4(6):e5950.
PMID: 19536329
PMC: 2694276.
DOI: 10.1371/journal.pone.0005950.
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies.
Wandel S, Egger M, Rangsin R, Nelson K, Costello C, Lewden C
Sex Transm Infect. 2008; 84 Suppl 1:i31-i36.
PMID: 18647863
PMC: 2569418.
DOI: 10.1136/sti.2008.029793.
The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds.
Stover J, Johnson P, Zaba B, Zwahlen M, Dabis F, Ekpini R
Sex Transm Infect. 2008; 84 Suppl 1:i24-i30.
PMID: 18647862
PMC: 2569834.
DOI: 10.1136/sti.2008.029868.